Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial Infarction

New England Journal of Medicine

Volumn 313, Issue 25, 1985, Pages 1557-1563

  Hamsten, Anders ^a   Wiman, Björn ^a   de Faire, Ulf ^a   Blombäck, Margareta ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR;

ADULT; AGE; BLOOD AND HEMOPOIETIC SYSTEM; DIAGNOSIS; FIBRINOLYSIS; HEART; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; PLASMA; PRIORITY JOURNAL;

EID: 0022354051     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198512193132501     Document Type: Article

References (40)

1. Ganz W, Geft I, Maddahi J, et al. Nonsurgical reperfusion in evolving myocardial infarction. J Am Coll Cardiol 1983; 1: 1247–53.
2. Ganz W, Geft I, Shah P, et al. Intravenous streptokinase in evolving acute myocardial infarction. Am J Cardiol 1984; 53: 1209–16.
3. Sobel BE, Geltman EM, Tiefenbrunn AJ, et al. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation 1984; 69: 983–990.
4. Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentration. Br Med J 1979; 1: 153–6.
5. Andersen P, Amesen H, Hjermann I. Hyperlipoproteinemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand 1981; 209: 199–202.
6. Simpson HCR, Mann JI, Meade TW, Chakrabarti R, Stiriing Y, Woolf L. Hypertriglyceridaemia and hypercoagulability. Lancet 1983; 1: 786–9.
7. Aimér L.-O., Nilsson IM. On fibrinolysis in diabetes mellitus. Acta Med Scand 1975; 198: 101–6.
8. Fuller JH, Keen H, Jarrett RJ, et al. Haemostatic variables associated with diabetes and its complications. Br Med J 1979; 2: 964–6.
9. Almér L.-O., Janzon L. Low vascular fibrinolytic activity in obesity. Thromb Res 1975; 6: 171–5.
10. Wiman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chem Acta 1983; 127: 279–288.
11. Urdén G, Blombäck M. Determination of tissue plasminogen activator in plasma samples by means of a radioimmunoassay. Scand J Clin Lab Invest 1984; 44: 495–502.
12. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitorio tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–436.
13. Wiman B, Chmielewska J, Rånby M. Inactivation of tissue plasminogen activator in plasma: demonstration of a complex with a new rapid inhibitor. J Biol Chem 1984; 259: 3644–7.
14. Nomenclature and criteria for diagnosis of ischemic heart disease: report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979; 59: 607–9.
15. Vermylen C, de Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen polymerization time (FPT test). Clin Chim Acta 1963; 8: 418–424.
16. Seligsohn U, Österud B, Rapaport SI. Coupled amidolytic assay for VII: its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978–988.
17. Savidge GF, Blombäck M, Blombäck B. Studies of factor VIII procoagulant activity in plasma and concentrates using a semi-automated thrombin generation assay. Thromb Res 1979; 16: 355–365.
18. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45–52.
19. Abildgaard U, Lie M, Ødegård OR. Antithrombin (heparin cofactor) assay with “new” chromogenic substrates (S-2238 and Cromozym TH). Thromb Res 1977; 11: 549–553.
20. Teger-Nilsson A.-C., Friberger P, Gyzander E. Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. Scand J Clin Lab Invest 1977; 37: 403–9.
21. Wiman B, Nilsson T. A new simple method for determination of C1-esterase inhibitor activity in plasma. Clin Chim Acta 1983; 128: 359–366.
22. Seidel J. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 1983; 29(Suppl): 1075–80.
23. Wahlefeld AW. Triglycerides: determination after enzymatic hydrolysis. In: Bergmeyer HU, ed. Methods of enzymatic analysis. New York: Academic Press, 1974:1831–5.
24. Burstein M, Scholnick HR. Lipoprotein-polyanion-metal interactions. Adv Lipid Res 1973; 11: 67–108.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
26. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, Iowa: Iowa State University Press, 1980.
27. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T. Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 1970; 43: 891–908.
28. Noble RP. Electrophoretic separation of plasma lipoproteins in agarose gel. J Lipid Res 1968; 9: 693–700.
29. Efendić S, Wajngot A, Cerasi E, Luft R. Insulin release, insulin sensitivity, and glucose tolerance. Proc Natl Acad Sci USA 1980; 77: 7425–9.
30. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265–270.
31. Chakrabarti R, Hocking ED, Fearnley GR, Mann RD, Attwell TN, Jackson D. Fibrinolytic activity and coronary-artery disease. Lancet 1968; 1: 98790.
32. Korsan-Bengtsen K, Wilhelmsen L, Elmfeldt D, Tibblin G. Blood coagulation and fibrinolysis in man after myocardial infarction compared with a representative population sample. Atherosclerosis 1972; 16: 83–88.
33. Rawles JM, Warlow C, Ogston D. Fibrinolytic capacity of arm and leg veins after femoral shaft fracture and acute myocardial infarction. Br Med J 1975; 2: 61–62.
34. Walker ID, Davidson JF, Hutton I, Lawrie TDV. Disordered “fibrinolytic potential” in coronary heart disease. Thromb Res 1977; 10: 509–520.
35. Franzén J, Nilsson B, Johansson BW, Nilsson IM. Fibrinolytic activity in men with acute myocardial infarction before 60 years of age. Acta Med Scand 1983; 214: 339–344.
36. Meade TW, North WRS, Chakrabarti R, et al. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet 1980; 1: 1050–4.
37. Arnesen H, Semb G, Hol R, Karlsen H. Fibrinolytic capacity after venous stasis in patients undergoing aorto-coronary by-pass surgery: relation to shunt occlusion. Scand J Haematol 1983; 30(Suppl 39):43–46.
38. Epstein SE, Rosing D.R., Brakman P, Redwood D.R., Astrup T. Impaired fibrinolytic response to exercise in patients with type-IV hyperlipoproteinaemia. Lancet 1970; 2: 631–4.
39. Cash JD. Platelet fibrinolysis and stress. In: Brinkhous KM, ed. Thrombosis — risk factors and diagnostic approaches. Stuttgart: Schattauer Verlag, 1972:93–97.
40. Markwardt F, Klöcking HP. Studies on the release of plasminogen activator. Thromb Res 1976; 8: 217–223.